Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

iRNA-CAR-T iRNA|CAR-T: An All-RNA Platform for Durable In Vivo Generation of Cancer-Specific CAR-T Cells

Coordinator
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Germany
Runs
1 January 2027 to 31 December 2031
Status
Running
EU funding
€1.4m
Total cost
€1.4m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101303292

What the project is doing

In the project's own words, from its summary on CORDIS.

I propose iRNA|CAR-T (integrating RNA-mediated CAR-T), a next-generation platform for the in vivo creation of chimeric antigen receptor (CAR) T cells using all-RNA genome editors delivered by lipid nanoparticles (LNPs). This approach directly addresses key limitations of current CAR-T therapies—complex ex vivo manufacturing and toxic lymphodepleting chemotherapy—by enabling CAR-T generation within the patient’s body, thereby simplifying manufacture, broadening patient access, and reducing treatment-related burden.

Focusing initially on CD19-directed CARs for B-cell malignancies, iRNA|CAR-T will establish a scalable in vivo CAR-T production platform, that is generalizable to all CAR-T indications.iRNA|CAR-T combines two all-RNA DNA-writing systems: R2 retrotransposons for inserting large gene fragments into genomic safe-harbour sites, and CRISPR prime editing (PE) for precise sequence modifications at the nucleotide level. Together, they transform transient RNA delivery into lasting genomic modifications enabling stable CAR integration, durable CAR-expression, and sustained CAR-T activity as well as selective expansion of CAR-T cells.

To enable in vivo application, I will employ LNPs—a clinically proven and scalable system for selective T cell delivery. Integrating LNPs with all-RNA DNA-writing tools establishes a fully RNA-based strategy for in vivo T cell engineering, enabling clinically-scalable in vivo CAR-T generation. During my postdoc, I provided the first demonstration of PE in primary human T cells gaining expertise in translating cutting-edge genome engineering technologies to primary T cell systems.

I will leverage this expertise to develop the iRNA|CAR-T platform for in vivo CAR-T production. Its simplicity and scalability will expand CAR-T therapy to new indications and, more broadly, establish a platform for in vivo gene editing and addition applicable to a wide range of genetic diseases.

Topics

Who is involved

OrganisationCityCountryRole
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-UniversitatWurzburgGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI